18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats.
Psychopharmacology October 1, 1998 Stanley D Glick, Isabelle M Maisonneuve, K E Visker et al. 45 citations
Two studies were conducted to assess, in vivo, potential anti-nicotinic effects of the iboga alkaloid ibogaine and its synthetic congener 18-methoxycoronaridine (18-MC). As previously demonstrated for ibogaine, using microdialysis, pretreatment (19h beforehand) with 18-MC (40 mg/kg, i.p.) significantly attenuated nicotine-induced dopamine release in the nucleus accumbens of awake and freely...
DOI: 10.1007/s002130050716 (opens in new tab)
Full text (opens in new tab)
Nicotine addiction treatment
Smoking cessation
Quit smoking
Tobacco dependence treatment
+17